A phase I trial of pulse calcitriol in patients with refractory malignancies: Pulse dosing permits substantial dose escalation

Cancer

Volumn 91, Issue 12, 2001, Pages 2431-2439

  Beer, Tomasz M ^a   Munar, Myrna ^a   Henner, W David ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

1 ,25 dihydroxycholecalciferol; 1,25 dihydroxyvitamin D; Calcitriol; Clinical trial; Neoplasm; Phase I; Vitamin D

Indexed keywords

CALCITRIOL;

AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCALCEMIA; LIVER DISEASE; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CALCITRIOL; CALCIUM; CELL DIVISION; DIET; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERCALCEMIA; MALE; MIDDLE AGED; NEOPLASMS; PULSE THERAPY, DRUG;

EID: 0035875881     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010615)91:12<2431::AID-CNCR1278>3.0.CO;2-3     Document Type: Article

References (46)

1. Noncalcemic actions of 1,25-dihydroxyvitamin D3 and clinical applications
2. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells
3. Vitamin D and prostate cancer: 1,25 Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines
4. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs
5. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro
6. 1 Alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line
7. Antiproliferative effect of 1,25-dihydroxyvitamin D3 and its analogs on human colon adenocarcinoma cells (CaCo-2): Influence of extracellular calcium
8. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells
9. Vitamin D receptor in endometrial carcinoma and the differentiation-inducing effect of 1,25-dihydroxyvitamin D3 on endometrial carcinoma cell lines
10. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3
11. 1,25-Dihydroxyvitamin D3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture
12. The effect of 1, 25-dihydroxyvitamin D3 on the growth of soft-tissue sarcoma cells as mediated by the vitamin D receptor
13. Correlation between the concentration of 1,25 alpha dihydroxyvitamin D3 receptors and growth inhibition, and differentiation of human osteosarcoma cells induced by vitamin D3
14. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3
15. Antiproliferative effects in vitro and in vivo of 1,25-dihydroxyvitamin D3 analog in a squamous cell carcinoma model system
16. Further studies of the effect of vitamin D on retinoblastoma. Inhibition with 1,25-dihydroxycholecalciferol
17. Toward therapeutic intervention of cancer by vitamin D compounds
18. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937
19. Translational control of p27Kip1 accumulation during the cell cycle
20. Growth inhibition of human keratinocytes by 1,25-dihydroxyvitamin D3 is linked to dephosphorylation of retinoblastoma gene product
21. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells
22. Novel regulatory actions of 1 alpha,25-dihydroxyvitamin D3 on the metabolism of polyphosphoinositides in murine epidermal keratin-ocytes
23. 1 Alpha,25-dihydroxyvitamin D3 inhibits normal human kera-tinocyte growth by increasing transforming growth factor beta 2 release
24. 1,25-Dihydroxyvitamin-D3 enhances antiproliferative effect and transcription of TGF-betal on human keratinocytes in culture
25. Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089
26. IGF-binding proteins in human prostate tumor cells: Expression and regulation by 1,25-dihydroxyvitamin D3
27. 1 Alpha,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells
28. Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination
29. Phase II trial of oral 1,25-dihydroxyvitamin D (Calcitriol) in hormone refractory prostate cancer
30. 1,25-Dihydroxyvitamin D3: In vivo and in vitro effects on human preleukemic and leukemic cells
31. Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer
32. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol)
33. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy
34. Actions of vitamin D3, analogs on human prostate cancer cell lines: Comparison with 1,25-dihydroxyvitamin D3
35. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system
36. Calcitriol inhibits p21waf1cip1 (p21) expression and sensitizes SCC cells to cisplatin cytotoxicity in vitro and in vivo
37. 1,25-Dihydroxycholecalciferol (1,25D3) and paclitaxel: A new therapeutic combination in prostate tumor model systems
38. The effect of renal function on changes in circulating concentrations of 1,25-dihydroxycholecalciferol after an oral dose
39. Blood concentrations of dihydroxylated vitamin D metabolites after an oral dose
40. Short-term course of 1,25(OH)2D3 stimulates osteoblasts but not osteoclasts in osteoporosis and osteoarthritis
41. The validation of dietary assessment
42. Using toxicity grades in the design and analysis of cancer phase I clinical trials
43. Design and analysis of phase I clinical trials
44. A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: Application to clinical studies
45. Consensus development conference statement